An interregional measles outbreak in Spain with nosocomial transmission, November 2017 to July 2018.
Healthcare workers
Outbreak
Spain
Waning immunity
measles
nosocomial transmission
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
medline:
1
5
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
ppublish
Résumé
Given sustained high vaccination coverage and enhanced surveillance for measles, Spain has been free of endemic measles transmission since 2014, achieving elimination certification from the World Health Organization in 2017. In November 2017, measles was introduced through an imported case travelling to the Valencian Community, causing an interregional outbreak. Here, we describe the outbreak using data reported to the national epidemiological surveillance network. The outbreak involved 154 cases (67 males, 87 females) notified in four regions; 148 were laboratory-confirmed and six epidemiologically linked. Most cases were adults aged 30-39 (n = 62, 40.3%) years. Sixty-two cases were hospitalised (40.3%) and 35 presented complications (22.7%). Two thirds of the cases (n = 102) were unvaccinated including 11 infants (≤ 1 year) not yet eligible for vaccination. The main route of transmission was nosocomial; at least six healthcare facilities and 41 healthcare workers and support personnel were affected. Sequencing of the viral nucleoprotein C-terminus (N450) identified genotype B3, belonging to the circulating MVs/Dublin.IRL/8.16-variant. Control measures were implemented, and the outbreak was contained in July 2018. The outbreak highlighted that raising awareness about measles and improving the vaccination coverage in under-vaccinated subgroups and personnel of healthcare facilities are key measures for prevention of future outbreaks.
Identifiants
pubmed: 37103785
doi: 10.2807/1560-7917.ES.2023.28.17.2200634
pmc: PMC10283469
doi:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Euro Surveill. 2019 Jul;24(29):
pubmed: 31339098
Euro Surveill. 2016;21(9):30152
pubmed: 26967661
Euro Surveill. 2019 Apr;24(17):
pubmed: 31039835
Euro Surveill. 2017 Apr 27;22(17):
pubmed: 28488998
Euro Surveill. 2018 May;23(20):
pubmed: 29790461
Wkly Epidemiol Rec. 2015 Jul 24;90(30):373-80
pubmed: 26211016
Vaccine. 2021 Sep 7;39(38):5346-5350
pubmed: 34393016
Am J Infect Control. 2013 Jul;41(7):661-3
pubmed: 23352075
J Med Virol. 2005 Jan;75(1):137-46
pubmed: 15543577
PLoS One. 2018 Jul 16;13(7):e0199975
pubmed: 30011283
Semergen. 2020 Mar;46(2):77-80
pubmed: 32061460
J Hosp Infect. 2018 Dec;100(4):e261-e263
pubmed: 29902487
Viruses. 2021 Oct 02;13(10):
pubmed: 34696412
Euro Surveill. 2015;20(39):
pubmed: 26537105
Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):455-466
pubmed: 34999974
Vaccine. 2012 Jun 8;30(27):3996-4001
pubmed: 22521843
J Infect Dis. 2016 Dec 15;214(12):1980-1986
pubmed: 27923955
Euro Surveill. 2019 Jan;24(3):
pubmed: 30670145
Euro Surveill. 2018 Jul;23(28):
pubmed: 30017024
Euro Surveill. 2011 Jul 21;16(29):
pubmed: 21801692
Enferm Infecc Microbiol Clin. 2010 Feb;28(2):73-4
pubmed: 20096973
Hum Vaccin Immunother. 2017 May 4;13(5):1078-1083
pubmed: 28059628
Clin Infect Dis. 2018 Oct 15;67(9):1315-1319
pubmed: 29878209
Euro Surveill. 2017 Aug 17;22(33):
pubmed: 28840827
Euro Surveill. 2017 Oct;22(42):
pubmed: 29067903
Rev Esp Salud Publica. 2015 Jul-Aug;89(4):365-79
pubmed: 26580792
PLoS One. 2013 Sep 10;8(9):e74754
pubmed: 24040337